- Home
- MBI vs DBVT Comparison
MBI vs DBVT Comparison
Compare MBI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBI
- DBVT
- Stock Information
- Founded
- MBI 1973
- DBVT 2002
- Country
- MBI United States
- DBVT France
- Employees
- MBI N/A
- DBVT N/A
- Industry
- MBI Property-Casualty Insurers
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MBI Finance
- DBVT Health Care
- Exchange
- MBI Nasdaq
- DBVT Nasdaq
- Market Cap
- MBI 228.2M
- DBVT 239.9M
- IPO Year
- MBI 1987
- DBVT N/A
- Fundamental
- Price
- MBI $4.41
- DBVT $8.35
- Analyst Decision
- MBI Buy
- DBVT Buy
- Analyst Count
- MBI 2
- DBVT 4
- Target Price
- MBI $6.25
- DBVT $14.81
- AVG Volume (30 Days)
- MBI 269.9K
- DBVT 102.2K
- Earning Date
- MBI 05-08-2025
- DBVT 07-29-2025
- Dividend Yield
- MBI N/A
- DBVT N/A
- EPS Growth
- MBI N/A
- DBVT N/A
- EPS
- MBI N/A
- DBVT N/A
- Revenue
- MBI $37,000,000.00
- DBVT $3,497,000.00
- Revenue This Year
- MBI N/A
- DBVT $1,700.53
- Revenue Next Year
- MBI N/A
- DBVT $535.67
- P/E Ratio
- MBI N/A
- DBVT N/A
- Revenue Growth
- MBI 285.71
- DBVT N/A
- 52 Week Low
- MBI $3.22
- DBVT $2.21
- 52 Week High
- MBI $7.46
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- MBI 46.89
- DBVT 42.98
- Support Level
- MBI $4.13
- DBVT $8.33
- Resistance Level
- MBI $5.00
- DBVT $9.92
- Average True Range (ATR)
- MBI 0.25
- DBVT 0.92
- MACD
- MBI 0.01
- DBVT -0.32
- Stochastic Oscillator
- MBI 32.18
- DBVT 4.53
About MBI MBIA Inc.
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiary.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.